BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38596399)

  • 1. Immune-Related Peripheral Neuropathy Associated with Immune Checkpoint Inhibitors: Case Report and Review of Literature.
    Bonilla CE; Ávila V
    Case Rep Oncol Med; 2024; 2024():8212943. PubMed ID: 38596399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
    Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
    Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report.
    Terashima T; Iwami E; Shimada T; Kuroda A; Matsuzaki T; Nakajima T; Sasaki A; Eguchi K
    BMC Pulm Med; 2020 Apr; 20(1):104. PubMed ID: 32334571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 8. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
    Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
    J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature.
    Piña Y; Evernden BR; Khushalani N; Margolin K; Tawbi H; Tran ND; Macaulay R; Forsyth P; Peguero E
    SAGE Open Med Case Rep; 2021; 9():2050313X211042215. PubMed ID: 34457306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. : A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature.
    Moon H; Kim SG; Kim SK; Kim J; Lee SR; Moon YW
    Medicine (Baltimore); 2022 Sep; 101(36):e30236. PubMed ID: 36086790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.
    Tesfaye S; Sloan G; Petrie J; White D; Bradburn M; Young T; Rajbhandari S; Sharma S; Rayman G; Gouni R; Alam U; Julious SA; Cooper C; Loban A; Sutherland K; Glover R; Waterhouse S; Turton E; Horspool M; Gandhi R; Maguire D; Jude E; Ahmed SH; Vas P; Hariman C; McDougall C; Devers M; Tsatlidis V; Johnson M; Bouhassira D; Bennett DL; Selvarajah D
    Health Technol Assess; 2022 Oct; 26(39):1-100. PubMed ID: 36259684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
    Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
    Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].
    Hashimoto R; Ueda T; Tsuji Y; Otsuka Y; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2020 Nov; 60(11):773-777. PubMed ID: 33115993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report.
    Li DH; Xiong XZ
    Clin Cosmet Investig Dermatol; 2024; 17():663-669. PubMed ID: 38524396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report.
    Zhang J; Zhang S; Xu S; Zhang X; Li J; Ji Z; Liu Q; Guo Z
    Iran J Immunol; 2023 May; 20(2):240-246. PubMed ID: 37179468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.